Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.51 |
| ▸ | CDK4 | P11802 | 7/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.51 |
| ▸ | BCR | P11274 | 3/20 | 0.51 |
| ▸ | PRKCA | P17252 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.49 |
| ▸ | CDK9 | P50750 | 4/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | CDK7 | P50613 | 2/20 | 0.49 |
| ▸ | CCNH | P51946 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14140367 | 0.88 | ABL1 (0.48) | CDK2CDK4ABL1BCREGFR | |
| SCHEMBL3605169 | 0.86 | CDK2 (0.51) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL3603519 | 0.85 | SYK (0.49) | CDK2CDK4ABL1BCREGFR | |
| SCHEMBL3607290 | 0.85 | ABL1 (0.43) | CDK2ABL1BCREGFRSRC | |
| SCHEMBL3603517 | 0.83 | ABL1 (0.41) | CDK2CDK4ABL1BCREGFR | |
| SCHEMBL3604092 | 0.80 | CDK1 (0.54) | CDK2CDK4EGFRCDK9CDK1 | |
| SCHEMBL3606836 | 0.78 | SYK (0.47) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL3602605 | 0.77 | CDK2 (0.50) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL3608990 | 0.77 | MAPT (0.52) | CDK2CDK4ABL1BCRPRKCA | |
| SCHEMBL3611125 | 0.76 | MAPT (0.52) | CDK2CDK4ABL1BCRPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CDK2 3078/4885CDK4 2775/4885ABL1 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.